TW200612983A - Vaccine - Google Patents

Vaccine

Info

Publication number
TW200612983A
TW200612983A TW094119691A TW94119691A TW200612983A TW 200612983 A TW200612983 A TW 200612983A TW 094119691 A TW094119691 A TW 094119691A TW 94119691 A TW94119691 A TW 94119691A TW 200612983 A TW200612983 A TW 200612983A
Authority
TW
Taiwan
Prior art keywords
hpv
composition
types
cancer
vaccine
Prior art date
Application number
TW094119691A
Other languages
English (en)
Chinese (zh)
Inventor
Serge Debrus
Marie-Therese Martin
Robert John Stephen
Jean Stephenne
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of TW200612983A publication Critical patent/TW200612983A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW094119691A 2004-06-16 2005-06-14 Vaccine TW200612983A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine

Publications (1)

Publication Number Publication Date
TW200612983A true TW200612983A (en) 2006-05-01

Family

ID=32750044

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094119691A TW200612983A (en) 2004-06-16 2005-06-14 Vaccine

Country Status (15)

Country Link
JP (1) JP2012102132A (cs)
KR (1) KR101359943B1 (cs)
CN (1) CN1976718B (cs)
CY (1) CY1113830T1 (cs)
DK (1) DK1758609T3 (cs)
ES (1) ES2394448T3 (cs)
GB (1) GB0413510D0 (cs)
HR (1) HRP20120930T1 (cs)
HU (3) HUS1500060I1 (cs)
LT (1) LTC1758609I2 (cs)
NL (3) NL300773I1 (cs)
PT (1) PT1758609E (cs)
SI (1) SI1758609T1 (cs)
TW (1) TW200612983A (cs)
ZA (1) ZA200610057B (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107080833A (zh) * 2009-04-10 2017-08-22 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)
CN103119168A (zh) * 2010-07-15 2013-05-22 不列颠哥伦比亚癌症局分支机构 人乳头瘤病毒e7抗原组合物及其用途
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN114716561B (zh) 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN114716560B (zh) 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Also Published As

Publication number Publication date
HUS1500059I1 (hu) 2017-10-30
SI1758609T1 (sl) 2013-01-31
CN1976718B (zh) 2012-10-10
NL300771I1 (cs) 2015-12-29
JP2012102132A (ja) 2012-05-31
ES2394448T3 (es) 2013-01-31
NL300774I1 (cs) 2015-12-29
PT1758609E (pt) 2012-12-21
NL300773I2 (cs) 2015-12-29
NL300774I2 (cs) 2015-12-29
NL300773I1 (cs) 2015-12-29
CY1113830T1 (el) 2016-06-22
ZA200610057B (en) 2008-02-27
DK1758609T3 (da) 2012-12-10
LTC1758609I2 (lt) 2017-05-10
HRP20120930T1 (hr) 2012-12-31
HUS1500061I1 (hu) 2016-01-28
HUS1500060I1 (hu) 2017-10-30
CN1976718A (zh) 2007-06-06
KR101359943B1 (ko) 2014-02-10
GB0413510D0 (en) 2004-07-21
KR20120123617A (ko) 2012-11-08
NL300771I2 (cs) 2015-12-29

Similar Documents

Publication Publication Date Title
WO2022221335A8 (en) Respiratory virus combination vaccines
EP4215543A3 (en) Hpv-specific binding molecules
AP1872A (en) Virus-like particles of human papillomavirus.
EP4219566A3 (en) Recombinant rsv antigens
WO2005046620A3 (en) Variable appearance tissue markings
EP4435105A3 (en) Asgr inhibitors for reduzing cholesterol levels
TW200531702A (en) Pharmaceutical preparation comprising an antibody against the egf receptor
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
MY139500A (en) Optimized expression of hpv 58 l1 in yeast
WO2011005595A3 (en) 2-5a analogs and their methods of use
WO2008024302A3 (en) Compounds for treating proliferative disorders
HK1198703A1 (en) Hpv chimaeric particle
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
CY1113830T1 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
PH12017501257A1 (en) Foot-and-mouth disease vaccine
PH12022552075A1 (en) Hpv vaccine
BRPI0810951B8 (pt) proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
WO2003039592A3 (de) Zelluläre impfstoffe mit adjuvanzien
WO2005017130A3 (en) Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
WO2009053601A3 (fr) Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant
SG153837A1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
WO2005047478A3 (en) Compositions and methods for regulation of tumor necrosis factor-alpha
WO2010023473A3 (en) Crystalline form of sunitinib and processes for its preparation